Certara, Inc. reported a revenue increase of 9% for the fiscal year ending December 31, 2025, reaching $418.8 million compared to $385.1 million in 2024. The growth was primarily driven by a significant rise in software sales, which surged by 18% to $183.3 million, and a 3% increase in service revenues, totaling $235.6 million. The company also noted a substantial improvement in its operating income, which rose to $21 million from a loss of $1.7 million in the previous year. Despite these positive trends, Certara recorded a net loss of $1.6 million, a significant reduction from the $12.1 million loss reported in 2024.
The company experienced notable operational changes, including the acquisition of Chemaxon, a leading cheminformatics software provider, for approximately $96.4 million. This acquisition is expected to enhance Certara's capabilities in drug discovery and biosimulation, positioning the company for further growth in the biopharmaceutical sector. Additionally, Certara launched its AI platform, Certara.AI, aimed at improving data connectivity and content generation for life sciences organizations, further expanding its product offerings.
Certara's customer base has also grown, with over 160,000 users licensed to use its software products, and the company has collaborated with more than 2,600 life sciences companies and academic institutions. The firm reported a net retention rate of 105.3% for 2025, indicating strong customer loyalty and expansion within existing accounts. The company has also expanded its geographic footprint, with operations in 28 countries, including significant presences in the U.S., Europe, and Asia.
Looking ahead, Certara's management expressed optimism about future growth, driven by the increasing adoption of model-informed drug development (MIDD) strategies and the ongoing demand for biosimulation solutions. The company aims to continue investing in its technology and expanding its service offerings to meet the evolving needs of the biopharmaceutical industry. However, management acknowledged potential risks, including regulatory changes and economic conditions that could impact customer spending on research and development.
About Certara, Inc.
Certara, Inc. is a global leader in biosimulation technology and solutions for the biopharmaceutical industry. It provides software and services that utilize modeling, simulation, and AI to optimize drug discovery, development, and regulatory processes. Its platforms support decision-making, improve success rates, and reduce costs across the entire drug lifecycle, serving pharmaceutical companies, regulators, and academic institutions worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.